Chronic effects of oral prostacyclin analogue on thromboxane A and prostacyclin metabolites in pulmonary hypertension

Abnormal biosynthesis of thromboxane and prostacyclin has been implicated in patients with primary pulmonary hypertension and secondary pulmonary hypertension associated with congenital heart disease, and could be involved in the pathogenesis of pulmonary vascular disease. The chronic effects of an oral prostacyclin analogue, beraprost sodium, on thromboxane and prostacyclin biosynthesis and on pulmonary circulation were investigated in 15 children with pulmonary hypertension. The plasma concentrations of thromboxane B, and 6‐keto‐prostaglandin F1α were measured, as was the urinary excretion of 11‐dehydro‐thromboxane B, and 2.3‐dinor‐6‐keto‐prostaglandin F1α, which are stable metabolites of thromboxane A, and prostacyclin, respectively. In patients with pulmonary hypertension, the plasma concentration of thromboxane B. and the ratio of thromboxane B, to 6‐keto‐prostaglandin F1α were greater than in healthy controls: 210 ± 49 versus 28 ± 4 pg/mL (P<6.05) and 32.6 ± 8.9 versus 5.7± 1.8 (p<0.01), respectively. After 3 months of administration of beraprost. the plasma concentration of thromboxane B, and the ratio of thromboxane B, to 6‐keto‐prostaglandin F were reduced significantly: 210 ± 49 to 98 ± 26 pg/mL (P < 0.01) and 32.6 ± 8.9 to 18.0 ± 6.7 (P < 0.05). respectively. In contrast, the plasma concentrations of 6‐keto‐prostaglandin F in patients were slightly but not significantly higher than in controls, and did not change significantly after administration of beraprost. The concentrations of 11‐dehydro‐thromboxane B, and 2.3‐dinor‐6‐keto‐prostaglandin F, in urine correlated significantly with thromboxane B, and 6‐keto‐prostaglandin F . respectively, in plasma. Beraprost improved the imbalance of thromboxane and prostacyclin biosynthesis and has a potential efficacy for preventing the progressive development of pathological changes in pulmonary vasculature.

[1]  I. Hashimoto,et al.  Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children. , 1997, Journal of cardiology.

[2]  T. Saji,et al.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.

[3]  T. Saito,et al.  [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension]. , 1996, Journal of cardiology.

[4]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[5]  T. Kamiya,et al.  Plasma Thromboxane B2 Concentration in Pulmonary Hypertension Associated With Congenital Heart Disease , 1994, Circulation.

[6]  J. Ritter,et al.  Thromboxane A2 and Prostacyclin Biosynthesis in Children and Adolescents With Pulmonary Vascular Disease , 1993, Circulation.

[7]  J. Deanfield,et al.  Impairment of Endothelium‐Dependent Pulmonary Artery Relaxation in Children With Congenital Heart Disease and Abnormal Pulmonary Hemodynamics , 1993, Circulation.

[8]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[9]  M. Rabinovitch Prostaglandins and structural changes in pulmonary arteries. , 1987, The American review of respiratory disease.

[10]  B. Brundage,et al.  Thromboxane synthetase inhibition in primary pulmonary hypertension. , 1987, Chest.

[11]  K. Moser,et al.  Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury. , 1986, Journal of applied physiology.

[12]  G. FitzGerald,et al.  Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. , 1983, Circulation.

[13]  Y. Sekino,et al.  Quantitative analysis of pulmonary vascular disease in simple cardiac anomalies with the Down syndrome. , 1983, The American journal of cardiology.

[14]  O. Ylikorkala,et al.  Plasma prostacyclin from birth to adolescence. , 1982, Archives of disease in childhood.